Contineum Therapeutics, Inc. Class A Common Stock

CTNM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$12,792-$16,040-$15,990-$14,565
Dep. & Amort.$81$79$78$75
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,569$2,418$2,569$0
Change in WC-$2,292-$1,934-$1,082$2,950
Other Non-Cash$237-$184$13$1,338
Operating Cash Flow-$12,197-$15,661-$14,412-$10,202
Investing Activities
PP&E Inv.-$98-$44-$47-$166
Net Acquisitions$0$0$0$0
Inv. Purchases-$18,641-$25,437-$33,691-$54,353
Inv. Sales/Matur.$33,680$39,365$48,653$45,131
Other Inv. Act.$0$0$0$0
Investing Cash Flow$14,941$13,884$14,915-$9,388
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$19,012$267$0$642
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$93-$176$24$0
Financing Cash Flow$19,105$91$24$642
Forex Effect$0$0$0$0
Net Chg. in Cash$21,849-$1,686$527-$18,948
Supplemental Information
Beg. Cash$20,784$22,470$21,943$40,891
End Cash$42,633$20,784$22,470$21,943
Free Cash Flow-$12,295-$15,705-$14,459-$10,368
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Statements & Key Stats | AlphaPilot